F. Borsa-Lebas

713 total citations
21 papers, 369 citations indexed

About

F. Borsa-Lebas is a scholar working on Infectious Diseases, Pharmacology and Virology. According to data from OpenAlex, F. Borsa-Lebas has authored 21 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 6 papers in Pharmacology and 6 papers in Virology. Recurrent topics in F. Borsa-Lebas's work include HIV Research and Treatment (6 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Drug Transport and Resistance Mechanisms (4 papers). F. Borsa-Lebas is often cited by papers focused on HIV Research and Treatment (6 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Drug Transport and Resistance Mechanisms (4 papers). F. Borsa-Lebas collaborates with scholars based in France, United States and New Zealand. F. Borsa-Lebas's co-authors include G. Humbert, A Leroy, François Caron, Véronique Lemee, J P Fillastre, Isabelle Étienne, Jean‐Christophe Plantier, Loïc Favennec, Gilles Gargala and J. Ballet and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

F. Borsa-Lebas

19 papers receiving 348 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Borsa-Lebas France 10 136 119 103 98 56 21 369
T. May France 11 226 1.7× 33 0.3× 191 1.9× 89 0.9× 21 0.4× 57 421
E.C.M. van Gorp Netherlands 9 262 1.9× 65 0.5× 50 0.5× 90 0.9× 47 0.8× 9 511
A. I. M. Hoepelman Netherlands 12 108 0.8× 61 0.5× 172 1.7× 64 0.7× 7 0.1× 21 349
M S Simberkoff United States 8 209 1.5× 123 1.0× 282 2.7× 27 0.3× 6 0.1× 8 470
M J Ossi United States 11 227 1.7× 122 1.0× 508 4.9× 14 0.1× 21 0.4× 12 669
Concha Amador Spain 10 116 0.9× 31 0.3× 290 2.8× 43 0.4× 23 0.4× 23 435
James Horton United States 6 332 2.4× 48 0.4× 253 2.5× 75 0.8× 4 0.1× 11 533
Danny J. Lancaster United States 12 414 3.0× 125 1.1× 423 4.1× 76 0.8× 48 0.9× 19 764
Christer Lidman Sweden 16 248 1.8× 33 0.3× 510 5.0× 41 0.4× 12 0.2× 32 657
L. Pou Spain 15 251 1.8× 104 0.9× 248 2.4× 17 0.2× 11 0.2× 26 521

Countries citing papers authored by F. Borsa-Lebas

Since Specialization
Citations

This map shows the geographic impact of F. Borsa-Lebas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Borsa-Lebas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Borsa-Lebas more than expected).

Fields of papers citing papers by F. Borsa-Lebas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Borsa-Lebas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Borsa-Lebas. The network helps show where F. Borsa-Lebas may publish in the future.

Co-authorship network of co-authors of F. Borsa-Lebas

This figure shows the co-authorship network connecting the top 25 collaborators of F. Borsa-Lebas. A scholar is included among the top collaborators of F. Borsa-Lebas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Borsa-Lebas. F. Borsa-Lebas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Piroth, Lionel, Stanislas Pol, Patrick Miailhes, et al.. (2015). Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study. Liver International. 35(8). 1950–1958. 15 indexed citations
2.
Etienne, Manuel, C. Chapuzet, Gilles Peytavin, et al.. (2014). Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy. Journal of Clinical Virology. 60(4). 428–430. 3 indexed citations
3.
Hocqueloux, Laurent, P. Choisy, G. Le Moal, et al.. (2012). Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study. PLoS ONE. 7(11). e49289–e49289. 6 indexed citations
4.
Borsa-Lebas, F., A. de La Blanchardière, Christophe Michau, et al.. (2012). Complicated Atazanavir-Associated Cholelithiasis: A Report of 14 Cases. Clinical Infectious Diseases. 55(9). 1270–1272. 17 indexed citations
5.
Sène, D., Stanislas Pol, Lionel Piroth, et al.. (2006). Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study. Epidemiology and Infection. 135(3). 409–416. 3 indexed citations
6.
Plantier, Jean‐Christophe, Véronique Lemee, Marie Gueudin, et al.. (2005). HIV-1 resistance genotyping on dried serum spots. AIDS. 19(4). 391–397. 61 indexed citations
7.
Lemee, Véronique, Gilles Gargala, J. Ballet, et al.. (2001). Successful Treatment of Metronidazole‐ and Albendazole‐Resistant Giardiasis with Nitazoxanide in a Patient with Acquired Immunodeficiency Syndrome. Clinical Infectious Diseases. 32(12). 1792–1794. 74 indexed citations
8.
Gilbert, Danièle, et al.. (1996). Similarity of Expression of Activation Markers and CD28 on γδ and αβ-Receptor T Cells in HIV Infection. Clinical Immunology and Immunopathology. 79(2). 189–193. 10 indexed citations
9.
Gueït, I., et al.. (1996). [Salmonella typhimurium cerebral abscess in a patient with HIV infection].. PubMed. 25(40). 2052–2052. 1 indexed citations
10.
11.
Fillastre, J. P., et al.. (1993). Does a Nonsteroidal Anti-Inflammatory Drug Modify the Pharmacokinetics of Pefloxacin and Ofloxacin?. Drugs. 45(Supplement 3). 295–296. 1 indexed citations
12.
Leroy, A, et al.. (1993). [Effect of ketoprofen on the pharmacokinetics of two fluoroquinolones in males].. PubMed. 41(4). 379–84. 1 indexed citations
13.
Leroy, A, J P Fillastre, F. Borsa-Lebas, Isabelle Étienne, & G. Humbert. (1992). Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrobial Agents and Chemotherapy. 36(12). 2794–2798. 82 indexed citations
14.
Jp, Fillastre, et al.. (1992). Effects of ketoprofen (NSAID) on the pharmacokinetics of pefloxacin and ofloxacin in healthy volunteers.. PubMed. 18(11-12). 487–92. 3 indexed citations
15.
Humbert, Guy, Guy Montay, A. Le Liboux, et al.. (1991). Influence of rifampin on the pharmacokinetics of pefloxacin. Clinical Pharmacology & Therapeutics. 50(6). 682–687. 11 indexed citations
16.
Fillastre, J. P., et al.. (1990). Pharmacokinetics of quinolones in renal insufficiency. Journal of Antimicrobial Chemotherapy. 26(suppl B). 51–60. 34 indexed citations
17.
Lecomte, F., et al.. (1987). Apport des modeles experimentaux au traitement des pyelonephrites. Médecine et Maladies Infectieuses. 17. 41–47.
18.
Humbert, G., F. Borsa-Lebas, & F. Lecomte. (1987). Les traitements courts de l'infection urinaire. Médecine et Maladies Infectieuses. 17(12). 791–794. 2 indexed citations
19.
Borsa-Lebas, F., F. Lecomte, G. Humbert, & E Dournon. (1985). La maladie de lyme : un cas autochtone confirmé sérologiquement. Médecine et Maladies Infectieuses. 15(1). 44–45. 1 indexed citations
20.
Humbert, G., E Dournon, F. Borsa-Lebas, & F. Lecomte. (1985). [Lyme disease: 2 new cases confirmed serologically].. PubMed. 14(38). 1973–1973. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. May Breakdown of academic impact, for papers by E.C.M. van Gorp Breakdown of academic impact, for papers by A. I. M. Hoepelman Breakdown of academic impact, for papers by M S Simberkoff Breakdown of academic impact, for papers by M J Ossi Breakdown of academic impact, for papers by Concha Amador Breakdown of academic impact, for papers by James Horton Breakdown of academic impact, for papers by Danny J. Lancaster Breakdown of academic impact, for papers by Christer Lidman Breakdown of academic impact, for papers by L. Pou
Rankless by CCL
2026